Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association's 84th Scientific Sessions

Gan & Lee Pharmaceuticals Florida New Jersey Austria Germany Switzerland United Kingdom Italy Spain Netherlands Belgium France United States of America

A phase 1b/2a trial evaluated once- and bi-weekly GZR18, a novel GLP-1 analog, in Chinese subjects with obesity/overweightPre-clinical studies evaluated the molecular and pharmacological properties of GZR4, an investigational once-weekly insulin analog Pre-clinical studies evaluated and characterized an ultra-long-acting basal insulin, GZR33, and its premixed formulation GZR101View original content:https://www.prnewswire.co.uk/news-releases/gan--lee-pharmaceuticals-to-present-groundbreaking-data-on-three-innovative-products-at-the-american-diabetes-associations-84th-scientific-sessions-302174998.html